Bayer Seeks Speedy EMA Review For Diabetic Kidney Disease Drug Finerenone
Executive Summary
The developers of three drugs are hoping the European Medicines Agency will decide that their products merit fast-tracking when they are submitted for review for potential pan-EU approval.